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Epigenetic histone modulations of PPARγ and related pathways contribute to 
olanzapine-induced metabolic disorders 
Abstract 
The antipsychotic drug olanzapine is widely used in the treatment of schizophrenia, bipolar and other 
mental disorders; however, it causes serious metabolic disorders, including dyslipidemia. Our previous 
studies have identified that olanzapine activated expression of the sterol regulatory element binding 
transcription factor 1 (SREBP-1) gene, a key transcriptional factor for lipogenesis in the liver and 
adipocytes. SREBP-1 has been reported to positively regulate the peroxisome proliferator-activated 
receptor gamma (PPARγ), a master regulator in the process of adipogenesis. This study aimed to 
investigate epigenetic modulations of the hepatic PPARγ pathway in olanzapine-induced lipid 
dysfunctions. Olanzapine led to significant increases of body weight gain, white adipose tissue, fasting 
triglyceride, and fat accumulation in the liver. A significant upregulation of PPARγ was observed in 
olanzapine-treated rats. ChIP-deep sequencing showed the increase of H3K4me2 binding on the whole 
gene loci of key regulators of adipogenesis and lipogenesis, the Pparg, Srebp-1, Cebps families (Cebpa, 
Cebpb and Cebpd), the Signal transducer and activator of transcription 5 families (Stat5a and Stat5b) and 
Klfs families (Klf9 and Klf15), as well as muscarinic M3 receptor (Chrm3). ChIP-qPCR revealed that 
H3K9me3 binding on the promoter of Pparg2 was significantly decreased. Consistently, KDM4B, KDM1A 
and PHF2, the three histone demethylases responsible for site-specific erasure of H3K9me, was 
increased in olanzapine-treated rats. These results suggested that olanzapine acted as stimuli to trigger 
the cascade of adipogenesis and lipogenesis through modulating hepatic histone modifications and 
subsequently upregulating key transcriptional factors. These findings provided new insight into effective 
strategies for the prevention and treatment of metabolic side-effects induced by antipsychotic 
medication. 
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The antipsychotic drug olanzapine is widely used in the treatment of schizophrenia, bipolar 22 
and other mental disorders; however, it causes serious metabolic disorders, including 23 
dyslipidemia. Our previous studies have identified that olanzapine activated expression of 24 
the sterol regulatory element binding transcription factor 1 (SREBP-1) gene, a key 25 
transcriptional factor for lipogenesis in the liver and adipocytes. SREBP-1 has been 26 
reported to positively regulate the peroxisome proliferator-activated receptor gamma 27 
(PPARγ), a master regulator in the process of adipogenesis. This study aimed to investigate 28 
epigenetic modulations of the hepatic PPARγ pathway in olanzapine-induced lipid 29 
dysfunctions. Olanzapine led to significant increases of body weight gain, white adipose 30 
tissue, fasting triglyceride, and fat accumulation in the liver. A significant upregulation of 31 
PPARγ was observed in olanzapine-treated rats. ChIP-deep sequencing showed the 32 
increase of H3K4me2 binding on the whole gene loci of key regulators of adipogenesis 33 
and lipogenesis, the Pparg, Srebp-1, Cebps families (Cebpa, Cebpb and Cebpd), the Signal 34 
transducer and activator of transcription 5 families (Stat5a and Stat5b) and Klfs families 35 
(Klf9 and Klf15), as well as muscarinic M3 receptor (Chrm3). ChIP-qPCR revealed that 36 
H3K9me3 binding on the promoter of Pparg2 was significantly decreased. Consistently, 37 
KDM4B, KDM1A and PHF2, the three histone demethylases responsible for site-specific 38 
erasure of H3K9me, was increased in olanzapine-treated rats. These results suggested that 39 
olanzapine acted as stimuli to trigger the cascade of adipogenesis and lipogenesis through 40 
modulating hepatic histone modifications and subsequently upregulating key 41 
transcriptional factors. These findings provided new insight into effective strategies for the 42 
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Acc1, CoA carboxylase1  49 
BAT, brown adipose tissue 50 
AMPK, AMP-activated protein kinase 51 
b.i.d, bis in die (twice a day) 52 
C/EBPs, CCAAT/ enhancer-binding proteins  53 
ChIP, Chromatin Immunoprecipitation  54 
EZH2, Enhancer of Zeste Homolog 2  55 
H3K4me, histone H3 methylations at 4 lysine residue  56 
H3K9me, histone H3 methylations at 9 lysine residue  57 
KLFs, Krüppel-like family of transcription factors 58 
NEFA, non-esterified fatty acid  59 
ORO, Oil-Red-O 60 
PPARγ, peroxisome proliferator-activated receptor gamma  61 
SGAs, second-generation antipsychotic drugs  62 
SREBP-1, Sterol regulatory element binding transcription factor 1  63 
STAT5, signal transducer and activator of transcription 5 64 
5 
 
TC, cholesterol  65 
TF, transcriptional factor  66 
TG, Total triglyceride 67 
TSS, transcriptional start sites 68 
WAT, white adipose tissue   69 
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1. Introduction 70 
Second-generation antipsychotic drugs (SGAs), such as olanzapine, are widely used in the 71 
treatment of schizophrenia, bipolar and other mental disorders; however, they cause weight 72 
gain/obesity and other serious metabolic disorders, including dyslipidemia (1, 2). 73 
Accumulated evidence showed that SGAs could directly impair lipid metabolisms that may 74 
further lead to insulin resistance, glucose intolerance and even type II diabetes (3-5). 75 
Therefore, a better understanding of the molecular mechanisms underlying antipsychotic-76 
induced dysregulation of lipid metabolisms is critical for developing effective strategies 77 
for prevention and treatment of these detrimental side-effects (5).  78 
Both clinical and animal studies have reported that olanzapine caused hepatic lipid and 79 
adipose accumulations (6-8). Lipogenesis and adipogenesis are regulated by a complex 80 
transcriptional cascade that requires a highly orchestrated and sequential activation of a 81 
large variety of transcriptional factor (TF) families (9, 10). Sterol regulatory element 82 
binding transcription factor 1 (SREBP-1) is a key TF in regulating the link between genes 83 
and lipid and cholesterol production (10). It has also been reported that SREBP-1 promotes 84 
peroxisome proliferator-activated receptor γ (PPARγ) expression through directly binding 85 
on the promoter of PPARg (11), as well as synthesizing endogenous PPARγ ligands (12). 86 
PPARγ is a master regulator in modulating the process of adipogenesis and lipid storage 87 
(13). Besides PPARγ and SREBP-1, CCAAT/ enhancer-binding proteins (C/EBPs; the 88 
basic leucine zipper family TFs characterized as a highly conserved bZIP domain at the C-89 
terminus), and the Krüppel-like family of transcription factors (KLFs; a kind of protein 90 
containing one or more zinc motifs), are also associated with activation of the adipogenesis 91 
network (9, 14). In addition, the signal transducer and activator of transcription 5 (STAT5, 92 
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including STAT5A and STAT5B) has been reported to enhance transcription of PPARγ in 93 
promoting adipogenesis, and is involved in lipid metabolism (15, 16). Previous reports 94 
from our laboratory and other laboratories have shown that olanzapine induced the 95 
upregulation of hepatic SREBP-1 expression (7, 17-19), but it is still unclear how hepatic 96 
PPARγ, and related C/EBPs, KLFs and STAT5 pathways are modulated by SGAs. 97 
Epigenetic regulation, such as histone modification, has also been reported to play a key 98 
role in progression of hepatic lipogenesis and adipogenesis (20-22). Histone modification, 99 
particularly acetylation and methylation on the special site of histone tails, dynamically 100 
regulates specific gene expression by altering the chromatin structure for facilitating (“open 101 
chromatin”) or restricting (“close chromatin”) TFs binding on DNA (21). For example, the 102 
histone 3 lysine 4 methylation of the 2 or 3 methyl groups (H3K4me2 or H3K4me3) is a 103 
mark of open chromatin promoting PPARγ and C/EBPs expression, while H3K9-104 
methylation (H3K9me2 or H3K9me3) is commonly restricted by closed chromatin 105 
modification (22). Furthermore, a list of position and cell type-specific histone 106 
methyltransferases (such as EHMT2 and KMT2C) and histone demethylases (such as 107 
KDM1A, KDM4B, PHF2) have been reported to regulate adipogenesis (21, 23). To date, 108 
however, histone modification of hepatic lipogenesis and adipogenesis associated with 109 
SGA-induced dysfunctions of lipid metabolism remain unexplored, and has therefore been 110 
investigated in this study. Furthermore, olanzapine is known to elicit its therapeutic effects 111 
predominantly through strong antagonistic affinities with dopaminergic D2 and serotonin 112 
5-HT2A receptors, and its metabolic side-effects through strong antagonistic affinities with 113 
5-HT2C and muscarinic M3 receptors (2, 24, 25). However, D2 and M3 receptors, but not 114 
5-HT2A/2C receptors, are expressed in the rat liver (26, 27); therefore, histone 115 
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modification of hepatic dopaminergic D2 and muscarinic M3 receptors has also been 116 
investigated. 117 
2. Materials and methods 118 
2.1 Animal housing and treatment 119 
Twenty-four female Sprague-Dawley rats weighing from 200g to 220g were purchased 120 
from the Animal Resource Centre (Perth, WA, Australia). After one week of environmental 121 
familiarization, all animals were housed in individual cages under environmentally 122 
controlled conditions (22 0C, with light cycle from 07:00 am–7:00 pm and dark cycle from 123 
7:00 pm–7:00 am), with free access to water and standard laboratory chow diet (3.9 kcal/g; 124 
10% fat, 74% carbohydrate and 16% protein) throughout the experiment period. The rats 125 
were trained to eat cookie dough pellets (0.3g, including 30.9% cornstarch, 30.9% sucrose, 126 
6.3% gelatin, 15.5% casein, 6.4% fiber, 8.4% minerals and 1.6% vitamins) without any 127 
drug twice a day for 1 week (28, 29). They were then treated orally with Olanzapine in 128 
0.3g cookie dough mixed with water (n=12; 3 mg/kg, b.i.d, Zyprexa, Eli Lilly, Indianapolis, 129 
USA), or vehicle (0.3g cookie dough mixed with water; Control, n=12) for nine weeks. It 130 
has been previously reported that, at this dosage, the drug reached 60–80% D2 receptor 131 
occupancy rates in the rat brain, and was effectively to induce metabolic side-effects in rats 132 
(7, 30, 31). Since olanzapine has a shorter half-life in rats than in humans (32), the drug 133 
was administrated twice a day. Food intake, water consumption and body weight were 134 
measured once a week, respectively. All of these procedures have been approved by the 135 
Animal Ethics Committee, University of Wollongong, Australia (AE12/26), in accordance 136 
with the Australian Code of Practice for the Care and Use of Animals for Scientific 137 
purposes (2004). 138 
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2.2 Liver and adipose tissue analysis 139 
After 9 weeks’ treatment, rats were randomly chosen to sacrifice after 2 hours (n=6 for 140 
each treatment group) or overnight drug-washout (15±1 hours of the final treatment) (n=6 141 
for each treatment group). Livers, white adipose tissue (WAT; including perirenal, 142 
periovary, inguinal and mesentery adipose tissue), and brown adipose tissue (BAT) were 143 
immediately dissected, weighed, and frozen in liquid nitrogen, and then stored at -80 0C 144 
until used for further analysis. The livers were cut at 14 µm in a Cryostat and stained by 145 
Oil-Red-O (ORO) and H&E staining. Images of ORO staining in the liver sections were 146 
measured using ImagerJ software (33). 147 
2.3 Blood collection and analysis of metabolic parameters 148 
Plasma was separated from 4-5 ml EDTA (20ml of a 5% solution) anticoagulated fasting 149 
blood after centrifuging at 4000 g for 10 min at 4 0C. Separated plasma was stored at -80 150 
0C until further analysis. Total triglyceride (TG), total cholesterol (TC) and non-esterified 151 
fatty acid (NEFA) concentration were measured using a Thermo Scientific Kit on a 152 
KoneLab 30i biochemistry analyzer (Thermo Fisher Scientific Oy, Vantaa, Finland).  153 
2.4. RNA isolation and gene expression analysis by real time qPCR 154 
Total RNA from liver tissue was prepared using the Aurum TM RNA Mini Kit (Bio-RAD, 155 
USA). cDNA was synthesized from 1 µg purified RNA using the iScriptTMRT Supermix 156 
Kit (Bio-RAD, USA). The mRNA expression of Pparg (Rn00440945_m1), Kdm1a 157 
(Rn01181029_m1), Ehmt2 (G9; Rn01525918_m1), Phf2 (Rn01435384_m1), Kdm4b 158 
(Rn01527809_m1), and Kmt2c (Mll3; Rn01410347_m1) was determined by qRT-PCR in 159 
duplicate using TaqMan®Gene Expression Assays (Thermo Fisher, USA) on a Quant 160 
Studio 5 Real-Time PCR System (Thermo Fisher,  USA). The cycling parameters were 95 161 
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0C for 10 minutes followed by 40 cycles (95 0C 15 s, 60 0C 1 min). All mRNA expression 162 
levels were normalized relative to four endogenous control genes, β-Actin (Actb) 163 
(Rn00667869 ml), Rplp0 (Rn03302271_gH), Hprt1 (Rn01527840_m1) and 164 
glyceraldehyde-3-phosphatedehydrogenase (Gapdh) (Rn01775763_gl). The 2−∆∆CT 165 
method was used to calculate the results. 166 
2.5 Western blot analysis 167 
Whole-protein lysates of liver tissue were extracted using 10 ml lysis buffer containing 9.8 168 
ml NP40 cell lysis buffer (Invitrogen, Camarillo, CA, USA), 100µl protease inhibitor 169 
cocktail (Sigma–Aldrich), 100µl 50 mM  β-Glycerophosphate (Invitrogen) and 33.3µl 170 
0.3M phenyl-methylsulfonyl fluoride (Sigma–Aldrich). Bio-Rad DCTM Assay was used 171 
to measure protein concentration. We loaded 30µg of proteins onto an 8% to 12% sodium 172 
dodecyl sulfate–polyacrylamide gel, transblotted onto polyvinylidene difluoride membrane 173 
(Bio-Rad), blocked with 5% skim milk in Tris-buffered saline with 0.1% Tween-20, and 174 
then incubated with the primary antibodies, including anti-PPARγ (1:1000, Abcam, 175 
ab209350) and anti-β-actin (1:2000, Merck, MAB1501). After incubating overnight, the 176 
membrane was then rinsed and incubated with anti-rabbit IgG, HRP-linked Antibody 177 
(1:2000, Cell Signaling, #7074s) or anti-mouse IgG, HRP-linked Antibody (1:5000, Cell 178 
Signaling, #7076s). The band complexes were recorded using Amersham Gel Imager (GE 179 
Healthcare, Life Science, USA) and quantified by a Fiji Image processing package. To 180 
ensure consistency, Western blot experiments were performed in duplicate. The results 181 
were presented as fold changes through divided by β-Actin and compared to the control.  182 
2.6 Chromatin immunoprecipitation (ChIP)-qPCR and ChIP-Seq 183 
ChIP experiments for H3K4me and K3K9me were performed using EpiQuik™ Tissue 184 
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Methyl-Histone H3-K4 ChIP Kit, EpiQuik™ Tissue Methyl-Histone H3-K9 ChIP Kit, and 185 
an EpiQuik™ Tissue ChIP Kit (Epigentek, USA) according to the manufacturer’s 186 
instructions. In brief, 40 mg of liver tissue was homogenized after it was cross-linked by 187 
1% formaldehyde using Precellys®24 homogenizer (Bertin Technologies, France). The 188 
chromatin DNA was then sheared to an average fragment length of 200–1,000 bp using a 189 
Branson 450 Digital Sonifier (Branson, USA). The sheared DNA was diluted with ChIP 190 
dilution buffer at a 1:1 ratio, transferred to a strip well for binding with chip-grade anti-191 
dimethyl-H3-K4, anti-trimethyl-H3-K9, or anti-normal mouse IgG (negative control) and 192 
incubated at room temperature for 60 minutes. Cross-Linked DNA was reversed using both 193 
a DNA release buffer containing Proteinase K and a reverse buffer in a 65 0C dry bath for 194 
one and half hours. Purified DNA was extracted using a spin column. The preliminary 195 
quantitation of the ChIP DNA was determined with NanoDrop 2000 (Thermo Fisher, USA). 196 
qPCR was performed with SYBR Green Master Mix (Qiagen, USA). The primers used for 197 
ChIP-qPCR were in accordance with the references (34). ChIP data (including input DNA) 198 
were normalized to negative control IgG and expressed as a percentage of input and fold 199 
enrichment. In parallel, ChIP DNA for H3K4me2 and H3K9me3 were further analyzed for 200 
deep sequencing. Paired-end sequencing libraries were sequenced using an Illumina 201 
Hiseq2500 50SE sequencer. BWA software was applied to align sequence reads or 202 
assembly contigs against the rat reference genome (rn6). Profiles of histone methylation 203 
on gene loci were visualized using Integrative Genomics Viewer (IGV) 2.5.0 software. 204 
2.7 Statistical analysis  205 
SPSS software (version 21.0, IBM, NY, USA) was used to analyze all data. The outliers 206 
were identified and removed using Boxplot. The Kolmogorov–Smirnov test was used to 207 
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examine the distribution of data from all experiments. Data were analyzed by a Student t-208 
test. A nonparametric Mann–Whitney U-test was performed for data without normal 209 
distribution. Statistical significance was accepted when p<0.05. The results were 210 
calculated as the mean ± SEM. 211 
3. Results 212 
3.1 The effects of Olanzapine in metabolic disturbance 213 
After 9-weeks’ treatment, olanzapine led to significant body weight gains compared to the 214 
control (p<0.05; Fig. 1A). Consistently, WAT mass was significantly increased in 215 
Olanzapine-treated rats (p<0.05), while no change in BAT mass was observed (p>0.05; 216 
Fig.1B). However, Olanzapine significantly increased liver weight (Fig 1A), as well as 217 
total ORO staining in lipids (both p<0.01) and lipid droplet size in livers (both p<0.05, 218 
Fig.1D and 1E). Meanwhile, the concentrations of plasma TG (p<0.001), TC (p<0.01), and 219 
NEFA (p<0.05) in the olanzapine group were significantly higher than in the control 220 
(Fig.1C).  221 
3.2 Dynamic modulation of PPARγ expression in the liver of Olanzapine treated rats  222 
The mRNA expression and protein levels of PPARγ in the liver were measured at two time 223 
points after the final drug treatment. Two hours after the final drug treatment, both protein 224 
and mRNA levels of PPARγ were significantly upregulated in the Olanzapine group (both 225 
p<0.05) compared to the control (Fig. 2A, 2C, 2E). However, after overnight drug-washout, 226 
PPARγ protein levels in Olanzapine-treated rats were significantly lower than in the control 227 
(p<0.05, Fig. 2B and 2D), while no significant difference was observed in mRNA 228 
expression from the control (p>0.05, Fig. 2F).  229 
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3.4 The effect of Olanzapine on hepatic H3K4me2 and H3K9me3 histone modifications- 230 
ChIP experiments 231 
To probe into the effect of olanzapine on histone modification in the liver, we investigated 232 
the effect of histone methylation on gene loci encoding transcriptional factors by 233 
performing ChIP experiments for H3K4me2 and H3K9me3 in liver samples of rats 234 
sacrificed two hours after the final treatment. The ChIP-seq experiment showed that an 235 
increased H3K4me2 binding was observed on a list of gene loci, especially in the 236 
transcriptional start sites (TSS), in rats treated with Olazapine, while no H3K4me2 binding 237 
was observed in these gene loci of the control group (Fig. 3 and Fig. 5). As shown in Fig. 238 
3A and 3B, Olanzapine induced a spike of H3K4me2 binding at the promotor region of the 239 
Pparg and Srebp1 gene loci. Olanzapine also increased H3K4me2 binding in other genes 240 
that had been confirmed to modulate the cascade of adipogenesis and lipogenesis, including 241 
Cebps (C/ebpα, C/ebpb and C/ebpd; Fig. 3 C-E), Klfs (Klf15, Fig. 3 F and Klf9, data 242 
unpresented), and Stat5 (Stat5a and Stat5b; Fig. 3 G-H). It is interesting that opposite 243 
results have been observed in H3K9me3 histone methylations in these genes. Although 244 
there was some H3K9me3 binding in Pparg gene locus of the control rats, Olanzapine 245 
inhibited H3K9me3 binding in this gene locus. There was no clear H3K9me3 binding in 246 
other gene loci (Fig. 3). These results were confirmed by the ChIP-qPCR for primers of 247 
Pparg1 and Pparg2; H3K9me3 on the promoter of Pparg2 was significantly lower in 248 
Olanzapine rats than in controls (p<0.01; Fig. 4B). No significant differences of H3K4me2 249 
bindings on Pparg2 were observed (Fig. 4A), while for PPARγ1, we did not observe 250 
significant changes in Olanzapine treated rats. 251 
In addition, as shown in Fig. 5A, Olanzapine increased H3K4me2 binding at the whole 252 
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gene loci of the muscarinic M3 receptor Chrm3 including the TSS region compared to the 253 
control rat. Although there was strong H3K9me3 binding in the Chrm3 gene locus of the 254 
control rats, Olanzapine inhibited H3K9me3 binding in this gene locus (Fig. 5 A). On the 255 
contrast, Olanzapine had not any effects on both H3K4me2 and H3K9me3 bindings in the 256 
dopamine D2 receptor Drd2 gene locus (Fig. 5B). 257 
3.5 Modulation of histone methyltransferases and demethylases  258 
In order to investigate the role of site-specific histone methyltransferases and demethylases 259 
in the current change of histone methylations, we measured mRNA levels of 260 
methyltransferases (EHMT2 for H3K9me; KMT2C for H3K4me) and demethylases 261 
(KDM1A for H3K9me and H3K4me; KDM4B and PHF2 for H3K9me). Two hours after 262 
the drug treatment, inhibitors of H3K9me such as Kdm1a, Kdm4b and Phf2 had 263 
significantly higher expression in the Olanzapine group than the control (Kdm1a and Phf2, 264 
p<0.01; Kdm4b, p<0.05; Fig. 6A-C). There was also a significantly increased expression 265 
of methyltransferase Ehmt2 at 2 hours of drugs treatment (p<0.05; Fig. 6D), however, no 266 
significantly change was observed in Kmt2c (p>0.05, Fig. 6E).  267 
 268 
4. Discussion 269 
In this research, we observed that chronic treatment of olanzapine caused weight gain and 270 
abnormal lipid metabolism including white fat accumulation in the liver of female rats. 271 
Upregulation of hepatic PPARγ was observed two hours after final drug treatment, but was 272 
not shown after 15 hours’ overnight drug-washout, which suggested a direct modulation of 273 
olanzapine on this master transcriptional factor in adipogenesis. Further ChIP-Seq analysis 274 
showed an enhanced H3K4me peak on the gene loci of Pparg, Srebp1, Cebps (C/ebpα, 275 
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C/ebpb and C/ebpd), Klfs (Klf9 and Klf15), Stat5 (Stat5a and Stat5b) and Chrm3, especially 276 
on the transcriptional specific site (TSS) in olanzapine treated rats. It has been reported 277 
previously that a heightened H3K4me mark on the TSS of genes promoted the activation 278 
of PPARγ, and some members of the C/EBPs and KLFs, which promoted the cascade of 279 
adipogenesis induced by olanzapine treatment (9, 22). H3K9me binding on the Pparg2 280 
promoter region was reduced by Olanzapine, which is supported by significant mRNA 281 
upregulation of H3K9me-specific histone demethylases, KDM4B, PHF2 and KDM1A. 282 
These results suggested that epigenetic histone modulation of hepatic PPARγ and related 283 
lipogenesis and adipogenesis pathways play a key role in olanzapine-induced metabolic 284 
disorders. 285 
 286 
Our understanding of the mechanism of adipogenesis is largely based on the in vitro murine 287 
cell lines and in vivo mice studies, and very little is known in humans (9). Further, the 288 
PPARγ modulations in metabolic syndromes observed from mouse models were not fully 289 
consistent with data from humans. For example, both dominant negative P465L 290 
heterozygous for the Pparg gene can cause abnormal adipose tissue distribution and high 291 
blood pressure in both mice and humans, while insulin resistance was observed only in 292 
humans (35, 36). On the other hand, the PPARγ mutant rat has been found to be a better 293 
model than mice in their physiological characteristics, which are more relevant to humans 294 
in studying PPARγ regulation of adipogenesis (37). Thus, the rat model used in this study 295 
would be suitable to investigate the hepatic PPARγ regulation of adipogenesis induced by 296 
olanzapine medication. In this data, hepatic PPARγ were increased in both transcriptional 297 
and protein levels after 2 hours’ of olanzapine treatment but not after 15 hours’ wash-out, 298 
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which strongly suggested that the PPARγ modulation for adipogenesis was directly 299 
promoted by olanzapine.   300 
 301 
The role of histone methylation in biological processes is different, depending on the lysine 302 
side of modification, including adipose differentiation. Generally, H3K4me correlates with 303 
gene activation, while H3K9me restricts gene expression (38). Our H3K4me2 ChIP-seq 304 
analysis is consistent with previous reports on histone methylation in the PPARγ pathways 305 
during adipogenesis using embryonic stem cells (ESCs) (39, 40). Our results showed that, 306 
compared to the control rats without clear H3K4me2 bindings, olanzapine treatment led to 307 
peak enrichment of H3K4me2 on the TSS of gene loci encoding Pparγ, Srebp1, Stat5a and 308 
Statb, and 2 Klfs (Klf9 and Klf15). In addition, H3K4me2 was enriched on the whole loci 309 
of C/ebpα, C/ebpβ and C/ebpδ. On the other hand, previous genome-wide profiling by 310 
ChIP-Seq revealed that H3K9me3, but not H3K4me2, is enriched on the whole loci 311 
(including TSS) of Pparγ genes in preadipocytes (41). Consistently, our ChIP-Seq data 312 
showed that H3K9me2 was enriched on the whole loci of Pparγ in the control rats, while 313 
this enrichment was largely reduced by olanzapine treatment. This was further confirmed 314 
by our ChIP-qPCR focused on the promoter area of the Pparγ2 isoform that a significantly 315 
lower H3k9me3 specific binding was caused by olanzapine treatment. Therefore, these 316 
results indicated these adipogenesis and lipogenesis related TFs may be upregulated by the 317 
increased methylation of the positive histone marks H3K4me, and decreased methylation 318 
of the negative histone marks H3K9me. 319 
 320 
Several histone site-specific methyltransferases and demethylases have been identified 321 
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which regulate adipogenesis (40). In this study, we investigated mRNA levels of KMT2C 322 
(MLL3) and EHMT2 (G9a) that can specially promote methylation on H3K4me and 323 
H3K9me, respectively. KMT2C (MLL3) could be recruited directly to the PPARγ promoter 324 
and increase H3K4me promoting adipogenesis, while a KMT2C (MLL3) knockout reduces 325 
H3K4me3 levels at PPARγ target genes leading to a 30-40% WAT reduction and 326 
triglyceride accumulation (42). However, unexpectedly, although olanzapine slightly 327 
increased the expression of MLL3 mRNA, it was not significant in this study, suggesting 328 
that olanzapine-enhanced H3K4me3 was not mainly due to the contribution of KMT2C. 329 
More recently, it has been reported that KMT2D (MLL4) is a major mammalian H3K4 330 
methyltransferase for enhanced activation of PPARγ and C/EBPβ (43). Therefore, further 331 
study should investigate whether olanzapine promoted H3K4me through KMT2D (MLL4). 332 
EHMT2 (G9a) is a major H3K9-specific methyltransferase, and acts as an inhibitor in 333 
PPARγ expression and adipogenesis (41, 44). It was unexpectedly to observe an increased 334 
expression of EHMT2 mRNA after 2 hours of the final olanzapine treatment. However, a 335 
previous study on 3T3-L1 cells had demonstrated that G9a was responsible for the 336 
epigenetic mechanism for the delayed expression of PPARγ through transactivation of 337 
C/EBPβ (45). It was interesting that we observed a reduced protein expression of PPARγ 338 
after 15 hours drug wash-out. Therefore the late decrease of PPARγ in this study may be 339 
modulated by EHMT2 (G9a).     340 
 341 
PHF2 and KDM4B (JMJD2B) are the H3K9-specific histone demethylases that have been 342 
identified as modulating the lipid metabolism process (46, 47). PHF2 potentiates 343 
adipogenesis by facilitating H3K9me histone demethylation at the C/EBPα promoter, while 344 
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a Phf2 overexpression may promote hepatic fat accumulation (46, 48). However, 345 
conditional knockout of Kdm4b in the liver of mice has been reported to play no role in the 346 
obesity phenotype (47). It is worthy of note that KDM1A (LSD1) is a histone demethylase 347 
for both H3K4me2 and H3k9me3 (38). It has been reported that knockdown KDM1A 348 
resulted in increased H3H9me3 binding at the C/EBPα promoter and inhibited 349 
adipogenesis, but increased energy expenditure through H3K4me2 regulation, while 350 
increased KDM1A gene expression by a high fat diet had the opposite effects, leading to 351 
fat accumulation (49). In this study, we observed an increased mRNA expression of Phf2, 352 
Kdm4b and Kdm1a (Lsd1) in the liver of rats after 2 hours’ treatment with olanzapine. 353 
Therefore, in consideration of the increased PPARγ expression and the inhibited profile of 354 
H3K9me3 binding on the Pparg2 promoter region, but not the C/EBPα promoter, under 355 
the olanzapine treatment, these results suggested that olanzapine recruited PHF2, KDM4B 356 
and KDM1A (LSD1) to erase histone methylation on the H3K9me mark, and subsequently 357 
reduced H3K9me3 levels on the Pparg promoter region leading to an inhibition of its 358 
expression.  359 
 360 
Finally, accumulating evidence confirms that the process of activation of transcriptional 361 
factors and chromatin remodeling events is dynamic and most happen within hours after 362 
initiation of adipocyte differentiation (50). The possible explanation was that the structure 363 
of the ligand binding domain for key TFs is dynamic, such as the PPARγ ligand (51, 52). 364 
Furthermore, the time of interaction between trans-acting factors and TFs corresponding 365 
DNA cis-acting elements is also a dynamic change. For example, mRNA peaks in 366 
KLF4 and KLF5 were at around 2 h and 6 h, respectively (53-56), while 367 
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KLF9 and KLF15 were at around day 6–8 in 3T3-L1 adipogenesis (54, 55). In the current 368 
study, we observed that both TFs and histone modifications were modulated for provoking 369 
PPARγ and related pathways after two hour’ of olanzapine treatment when the blood drug 370 
concentration peaked (57), while this provocation retreated when the drug was washed out. 371 
These indicated that epigenetic regulation through histone modifications in hepatic PPARγ 372 
and related pathways was activated by the olanzapine medication. 373 
 374 
The vagal nerve innervates and regulates liver metabolisms via muscarinic M3 receptors 375 
in hepatocytes, since the M3 receptor is the only subtype of muscarinic receptors expressed 376 
in the rodent liver/hepatocytes (27, 58). Our previous studies have revealed that the hepatic 377 
M3 receptor was significantly upregulated by chronic olanzapine treatment and contributed 378 
to olanzapine-induced dyslipidemia in rats (7). In this study, we observed an increased 379 
H3K4me2 but decreased H3K9me3 on the Chrm3 gene loci. Therefore, the upregulated 380 
hepatic M3 receptors by chronic olanzapine treatment could be modulated through 381 
increased H3K4me2 methylation and decreased H3K9me3 methylation on the Chrm3. It is 382 
interesting that olanzapine did not have any effects on methylation of both H3K4me2 and 383 
H3K9me3 on the Drd2 gene locus in this study, which is consistent with a previous report 384 
that antipsychotic drug sulpiride (also a dopaminergic D2 receptor antagonist) did not 385 
directly act at the D2 receptors of the rat liver in regulating functions of hepatic 386 
Cytochrome P450 enzymes (59). These findings suggest that, although olanzapine has high 387 
binding affinities to D2, 5-HT2A/2C, and M3 receptors, it may modulate hepatic functions 388 
via directly acting at M3 but not D2 and 5-HT2A/2C receptors. A recent study found that 389 
activation of M3 receptors reduced lipid synthesis in hepatocytes via activation of AMPKα 390 
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(60), while olanzapine, as a M3 antagonist, has been found to increase lipogenesis via 391 
deactivation of AMPKα (61, 62). Since it has been established that  AMPK plays a key role 392 
in the modulation of histone H3 methylation and demethylation (63), olanzapine may 393 
provoked histone regulation in the PPARγ pathway via the hepatic M3 receptor-AMPK 394 
pathway (Fig. 7). On the hand, as a cationic amphiphile, olanzapine can penetrate cellular 395 
membranes and, therefore, interferes with lipid organization and disrupts lysosomal 396 
function (3, 64). Olanzapine has been reported to directly inhibit cholesterol biosynthesis 397 
and disrupt cholesterol intracellular trafficking that leads an up-regulation of SREBPs (3, 398 
65), while it is unknown whether these direct lipid interferences have any effects on 399 
epigenetic modulations. It is also worthy to note that olanzapine could direct interact with 400 
nuclear receptors, such as the liver X receptor. Although a previous in vitro study found 401 
that olanzapine did not directly activate the liver X receptor in CHO-7 cells (a Chinese 402 
hamster ovarian cell line) (65), our recent study showed that olanzapine increased the 403 
expression of the liver X receptor in HepG2 cells (a human hepatoma cell line) (17). Using 404 
HepG2 cells, recently, the liver X receptor has been reported to upregulate histone H3K9 405 
demethylase JMJD2B leading an increased expression of PPArγ2 (66). In fact, JMJD2B 406 
(KDM4B) has been found to be significantly increased in the liver of rats treated with 407 
olanzapine in this study. Therefore, independently from acting via the M3 receptor-AMPK 408 
pathway, olanzapine may penetrate cellular membranes and regulate histone modifications 409 
via acting at the liver X receptor and possibly other nuclear receptors in the hepatocytes 410 
(Fig. 7). More studies are important to further confirm these regulation pathways. 411 
 412 
Taken together, this study is the first to demonstrate the time-dependent epigenetic 413 
21 
 
regulation of key transcriptional factors in the process of hepatic lipogenesis and 414 
adipogenesis induced by olanzapine treatment. The results clearly suggested that histone 415 
modifications (Fig. 7) could be a molecular mechanism underlying olanzapine induced 416 
metabolic disorders, particularly lipid metabolic dysfunctions. It provided us with a new 417 
insight to find effective strategies for prevention and treatment of adverse metabolic events 418 
induced by olanzapine and other antipsychotic drugs.  419 
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Chemical compounds 656 
 657 
Olanzapine (PubChem CID: 4585) 658 





Figure 1. The effects of olanzapine on (A) body gain and liver weight, (B) weight of 662 
white adipose (WAT) and brown adipose tissue (BAT), (C) plasma triglyceride (TG), 663 
total cholesterol (TC) and non-esterified fatty acid (NEFA) (D) Oil-Red-O (ORO) 664 
staining of liver sections. Insert images were magnified eight times to show the lipid 665 
staining morphology. (E)  Data from ORO staining of liver sections were presented. The 666 





Figure 2 Expression of PPARγ at 2 hours or 15 hours after final Olanzapine treatment. 670 
(A-B) The representative images of Western blot for PPARγ (57-KDa) and β-actin (43-671 
KDa; as loading controls). (C-D) relative protein levels of PPARγ. (E-F) mRNA expression 672 
of PPARγ. Abbreviations: 2H, 2 hours after final drug treatment; 15H, 15 hours drug wash-673 






Figure 3. ChIP-Seq profiles - snapshots of H3K4me2 and H3K9me3 binding on (A) 678 
Pparg, (B) Srebp1, (C) Cebpa, (D) Cebpb, (E) C/ebpd, (F) Klf15, (G) Stat5a, and (H) 679 
Stat5b gene loci. ChIP-Seq on H3K4me2 and H3K9me3 were performed in the liver 680 
samples of rats at 2 hours after final drugs treatment. Enrichment of peaks was visualized 681 
using IGV-2.5.0 software.  682 
 683 





Figure 4. ChIP-qPCR analyses of histone methylations on PPARγ2 promoter at 2 687 
hours after final drugs treatment. Histone modifications were measured by using ChIP-688 
qPCR with antibodies against (A) H3k4me2 (active mark), (B), H3K9me3 (inactive mark) 689 
in the liver of rats treated with olanzapine or control (n=6/group). *p <0.05, vs. control.  690 






Figure 5. ChIP-Seq profiles - snapshots of H3K4me2 and H3K9me3 binding on (A) 694 
muscarinic M3 receptor Chrm3, and (B) dopamine D2 receptor Drd2 gene loci. ChIP-695 
Seq on H3K4me2 and H3K9me3 were performed in the liver samples of rats at 2 hours 696 
after final drugs treatment. Enrichment of peaks was visualized using IGV-2.5.0 software. 697 
 698 





Figure 6. Effects of olanzapine treatment on histone methyltransferases (HMTs) and 702 
histone demethylase (HDMs). mRNA levels of specific HMTs and HDMs contributing to 703 
H3K4me and H3K9me at 2 hours (A-E) or 15 hours (F-J) after the final drug treatment 704 
(n=6/group). KMT2C (MLL3) is an HMT for H3K4me; KDM1A (LSD) is an HDM that 705 
erases methylation of both H3K4 and H3K9; KDM4B (JMJD2B) and Plant homeodomain 706 
finger 2 (PHF2) are HDMs that erase methylation of H3K9. EHMT2 (G9a) is a HMT that 707 
catalyses methylation of histone H3K9. Abbreviations: 2H, 2 hours after final drug 708 
treatment; 15H, 15 hours drug wash-out.  *p <0.05, **p <0.01: vs. control.  709 





Figure 7. A schematic diagram of histone modifications for epigenetic regulation of 713 
hepatic PPARγ and related pathways leading to increased lipogenesis and 714 
adipogenesis contributing to olanzapine-induced metabolic disorders. (The dashed 715 
arrows indicate the proposed regulation pathways based on previous findings from our and 716 
other laboratories (7, 17, 60, 61,63, 66)) 717 
 718 
